Similar articles

• [The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer].

  Honda S, Toi M, Shimizu S, Hayashi K, Tominaga T. Honda S, et al. Gan To Kagaku Ryoho. 1997 Apr;24(6):679-83. Gan To Kagaku Ryoho. 1997. PMID: 9126304 Clinical Trial. Japanese.
• [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].

  Inaji H, Sakai K, Oka T, Ozawa K, Saito Y, Senoo T, Taguchi T, Terasawa T, Nakao K, Mori T, Koyama H, Oshima A. Inaji H, et al. Gan To Kagaku Ryoho. 2006 Oct;33(10):1423-9. Gan To Kagaku Ryoho. 2006. PMID: 17033231 Clinical Trial. Japanese.
• [Adriamycin/cyclophosphamide: current standard in the adjuvant therapy of breast carcinoma? Or: how should one really put this question?].

  Cavalli F. Cavalli F. Schweiz Med Wochenschr. 1994 Oct 29;124(43):1882-4. Schweiz Med Wochenschr. 1994. PMID: 7973514 Clinical Trial. German. No abstract available.
• [CMF or CAF combination chemotherapy for breast cancer].

  Ota J. Ota J. Gan To Kagaku Ryoho. 1996 Dec;23(14):1886-90. Gan To Kagaku Ryoho. 1996. PMID: 8978791 Review. Japanese.
• [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].

  Tamura K. Tamura K. Rinsho Ketsueki. 2009 Apr;50(4):276-81. Rinsho Ketsueki. 2009. PMID: 19404020 Review. Japanese. No abstract available.